Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.

Item

http://www.wikidata.org/entity/Q45913413

Q45913413

about

Testing for ROS1 in non-small cell lung cancer: a review with recommendations Developmental transcriptome analysis and identification of genes involved in formation of intestinal air-breathing function of Dojo loach, Misgurnus anguillicaudatus Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection.

P2860

Q28070062-47E710A4-1BE1-48B9-B3E1-E4817D42F63C Q36108554-F857119C-AC11-421F-A5F9-46C8F4BA8BAD Q38833185-47E31488-BF76-46F1-B1FA-3991D84D81B5 Q47146662-9B318F86-1506-41F4-B04F-D07DB3C98532 Q47906170-C4E471D0-CBD2-46BD-863E-81189C0A01AA Q55027244-319EA7B7-B69D-49C2-B0FE-2DD9E154B535

P2860

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.

Item

http://www.wikidata.org/entity/Q45913413

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Combined analysis of rearrange ...... d their clinical significance.

@en

Combined analysis of rearrange ...... d their clinical significance.

@nl

type

Item

label

Combined analysis of rearrange ...... d their clinical significance.

@en

Combined analysis of rearrange ...... d their clinical significance.

@nl

prefLabel

Combined analysis of rearrange ...... d their clinical significance.

@en

Combined analysis of rearrange ...... d their clinical significance.

@nl

P1476

Combined analysis of rearrange ...... d their clinical significance.

@en

P2093

Bin Jiang

http://www.w3.org/2001/XMLSchema#string

Bo Deng

http://www.w3.org/2001/XMLSchema#string

Fang Liu

http://www.w3.org/2001/XMLSchema#string

Jinghai Zhou

http://www.w3.org/2001/XMLSchema#string

Kai Qian

http://www.w3.org/2001/XMLSchema#string

Kun Li

http://www.w3.org/2001/XMLSchema#string

Poming Kang

http://www.w3.org/2001/XMLSchema#string

Quan Zhang

http://www.w3.org/2001/XMLSchema#string

Qunyou Tan

http://www.w3.org/2001/XMLSchema#string

Ruwen Wang

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Lung cancer: epidemiology, etiology, and prevention

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Global cancer statistics, 2012

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.

P2888

s00280-016-2969-y

P304

583-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-2969-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039916837

http://www.w3.org/2001/XMLSchema#string

P698

26842788

http://www.w3.org/2001/XMLSchema#string

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.

about

P2860

P2860

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698